N-Phenylacetyl-L-prolylglycine ethyl ester

From Wikipedia, the free encyclopedia
  (Redirected from Noopept)
Jump to navigation Jump to search
N-Phenylacetyl-L-prolylglycine ethyl ester
Noopept.svg
Noopept.png
Clinical data
Trade names Noopept
Synonyms N-Phenylacetyl-L-prolylglycine ethyl ester; GVS-111
Legal status
Legal status
  • US: Unscheduled Not FDA approved
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
Formula C17H22N2O4
Molar mass 318.367 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

N-Phenylacetyl-L-prolylglycine ethyl ester is promoted as a nootropic and is a prodrug of cycloprolylglycine.[1] Other names include the brand name Noopept (Russian: Ноопепт), developmental code GVS-111; proposed INN omberacetam.[1][2][3]

Its synthesis was first reported in 1996.[1] It is orally available, and as of 2017 its metabolism and elimination half-life were not well understood, as cycloprolylglycine had not been measured in humans following administration.[1]

As of 2017 there had been many studies conducted in cells and in animal models, and there had been one clinical trial with 41 subjects, which compared Noopept and piracetam in people with traumatic brain injury.[1]

References[edit]

  1. ^ a b c d e "Noopept Information". Examine.com. Retrieved 6 April 2017. 
  2. ^ "Proposed INN List 117" (PDF). WHO Drug Information. 31 (2): 308. 2017. 
  3. ^ "GVS 111". AdisInsight. Retrieved 12 May 2018.